These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Genetically determined variability in acetylation and oxidation. Therapeutic implications. Clark DW Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977 [TBL] [Abstract][Full Text] [Related]
3. The quantitative disposition of procainamide and N-acetylprocainamide in the rat. Schneck DW; Grove K; Dewitt FO; Shiroff RA; Hayes AH J Pharmacol Exp Ther; 1978 Jan; 204(1):219-25. PubMed ID: 619132 [TBL] [Abstract][Full Text] [Related]
4. Polymorphic acetylation procainamide in man. Reidenberg MM; Drayer DE; Levy M; Warner H Clin Pharmacol Ther; 1975 Jun; 17(6):722-30. PubMed ID: 237647 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the acetylation of procainamide and sulfadimidine in man. Frislid K; Berg M; Hansteen V; Lunde PK Eur J Clin Pharmacol; 1976 Mar; 09(5-6):433-8. PubMed ID: 971707 [TBL] [Abstract][Full Text] [Related]
7. Significance of acetylator phenotype in pharmacokinetics and adverse effects of procainamide. Ylitalo P; Ruosteenoja R; Leskinen O; Metsä-Ketelä T Eur J Clin Pharmacol; 1983; 25(6):791-5. PubMed ID: 6198178 [TBL] [Abstract][Full Text] [Related]
8. Acecainide pharmacokinetics in normal subjects of known acetylator phenotype. Coyle JD; Boudoulas H; Lima JJ Biopharm Drug Dispos; 1991 Nov; 12(8):599-612. PubMed ID: 1724922 [TBL] [Abstract][Full Text] [Related]
9. Capacity-limited elimination of procainamide in man. Tilstone WJ; Lawson DH Res Commun Chem Pathol Pharmacol; 1978 Aug; 21(2):343-6. PubMed ID: 694230 [TBL] [Abstract][Full Text] [Related]
10. Acetylation of procainamide in man and its relationship to isonicotinic acid hydrazide acetylation phenotype. Gibson TP; Matusik J; Matusik E; Nelson HA; Wilkinson J; Briggs WA Clin Pharmacol Ther; 1975 Apr; 17(4):395-9. PubMed ID: 1122681 [TBL] [Abstract][Full Text] [Related]
11. Effect of coadministration of procainamide and isoniazid on each other's acetylation pathway. Schneck DW; Sprouse JS; Shiroff RA; Vary JE; DeWitt FO; Hayes AH Pharmacology; 1979; 18(1):34-41. PubMed ID: 419159 [TBL] [Abstract][Full Text] [Related]
12. Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. Woosley RL; Drayer DE; Reidenberg MM; Nies AS; Carr K; Oates JA N Engl J Med; 1978 May; 298(21):1157-9. PubMed ID: 306574 [TBL] [Abstract][Full Text] [Related]
13. The relationship between the metabolism of procainamide and sulfamethazine. Giardina E-GV ; Stein RM; Bigger JT Circulation; 1977 Feb; 55(2):388-94. PubMed ID: 832354 [TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype. Lima JJ; Conti DR; Goldfarb AL; Tilstone WJ; Golden LH; Jusko WJ J Pharmacokinet Biopharm; 1979 Feb; 7(1):69-85. PubMed ID: 458558 [TBL] [Abstract][Full Text] [Related]
17. Kinetics of procainamide and N-acetylprocainamide in renal failure. Gibson TP; Atkinson AJ; Matusik E; Nelson LD; Briggs WA Kidney Int; 1977 Dec; 12(6):422-9. PubMed ID: 609192 [TBL] [Abstract][Full Text] [Related]
18. Significance of the acetylation phenotype and the therapeutic effect of procainamide. Schröder P; Klitgaard NA; Simonsen E Eur J Clin Pharmacol; 1979 Feb; 15(1):63-8. PubMed ID: 84761 [TBL] [Abstract][Full Text] [Related]
19. Effect of exercise on plasma levels and urinary excretion of sulphadimidine and procainamide. Ylitalo P; Hinkka H Int J Clin Pharmacol Ther Toxicol; 1985 Oct; 23(10):548-53. PubMed ID: 4066079 [TBL] [Abstract][Full Text] [Related]
20. Ethanol interaction with drug acetylation in vivo and in vitro. Olsen H; Mørland J Pharmacol Biochem Behav; 1983; 18 Suppl 1():295-300. PubMed ID: 6634843 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]